MilliporeSigma, Billerica, MA, United States.
MilliporeSigma, Billerica, MA, United States.
Methods. 2019 Apr 1;158:69-76. doi: 10.1016/j.ymeth.2018.10.018. Epub 2018 Oct 28.
Quantitation of biomarkers in biofluids plays a central role in basic research to management of patient care and is routinely used in clinical laboratories and academic institutions. Standard immunoassays, such as an enzyme-linked immunosorbent assay (ELISA), have provided understanding of both normal and pathological processes for many decades. However, in more recent decades, new immunoassay technologies have uncovered numerous analytes in blood that were once undetectable using traditional ELISAs. To meet this new challenge for quantifying low abundant proteins in biofluids, Single Molecule Counting (SMC™) technology was developed. This new technology is a combination of improvements to both the immunoassay procedure as well as the instrument. The aim of this article is to introduce the new SMCxPRO™ instrument, xPRO Acquisition and Analysis software, and the high sensitivity immunoassay kits validated on this instrument for the detection of low abundant proteins in biofluids, such as serum and plasma. Using this new technology platform, biomarkers that were once unquantifiable can now be quantitated in both normal and diseased biofluids.
生物流体中生物标志物的定量在基础研究到患者护理管理中起着核心作用，并且在临床实验室和学术机构中经常使用。标准免疫测定，如酶联免疫吸附测定（ELISA），几十年来为许多正常和病理过程提供了认识。然而，在最近几十年，新的免疫测定技术在血液中发现了许多曾经使用传统 ELISA 无法检测到的分析物。为了应对生物流体中低丰度蛋白质定量的这一新挑战，开发了单分子计数（SMC™）技术。这项新技术是对免疫测定程序和仪器的改进的结合。本文的目的是介绍新的 SMCxPRO™仪器、xPRO 采集和分析软件以及在该仪器上验证的用于检测生物流体（如血清和血浆）中低丰度蛋白质的高灵敏度免疫测定试剂盒。使用这个新的技术平台，曾经无法定量的生物标志物现在可以在正常和患病的生物流体中进行定量。
